» Articles » PMID: 19387337

Prevention of Pancreatic Cancer by the Beta-blocker Propranolol

Overview
Specialty Oncology
Date 2009 Apr 24
PMID 19387337
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the leading causes of cancer deaths and is unresponsive to existing therapy. Smoking and alcohol-induced pancreatitis are among the risk factors for PDAC. We have previously reported that beta-adrenergic receptors (beta-ARs) stimulate the proliferation and migration of human PDAC cells in vitro by cAMP-dependent signaling and that the nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activates this pathway directly in vitro while additionally stimulating the release of noradrenaline/adrenaline by binding to alpha7 nicotinic acetylcholine receptors (alpha7 nAChR) in hamsters. In this study, we have tested the hypothesis that the beta-AR antagonist propranolol prevents the development of PDAC induced in hamsters with ethanol-induced pancreatitis by NNK. We found that propranolol had strong cancer preventive effects in this animal model. Western blots of pancreatic duct cells and PDAC cells harvested by laser capture microscopy showed significant upregulation of the alpha7 nAChR associated with significant inductions of p-CREB, p-ERK1/2, and increases in epidermal growth factor and vascular endothelial growth factor in PDAC cells of hamsters not treated with propranolol. These effects were reversed by treatment with propranolol. Our data suggest that propranolol may prevent the development of PDAC by blocking cAMP-dependent intracellular signaling, cAMP-dependent release of epidermal growth factor, and PKA-dependent release of vascular endothelial growth factor while additionally downregulating the alpha7 nAChR by inhibiting cAMP-mediated subunit assembly. We conclude that increased cAMP signaling is an important factor that drives the development and progression of PDAC and that the inhibition of cAMP formation is a promising new target for the prevention and adjuvant therapy of PDAC.

Citing Articles

Pancreatic Cancer: A Review of Risk Factors.

Grigorescu R, Husar-Sburlan I, Gheorghe C Life (Basel). 2024; 14(8).

PMID: 39202722 PMC: 11355429. DOI: 10.3390/life14080980.


Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts.

Koltai T, Fliegel L Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931411 PMC: 11206832. DOI: 10.3390/ph17060744.


The Crosstalk between Nerves and Cancer-A Poorly Understood Phenomenon and New Possibilities.

Benzaquen D, Lawrence Y, Taussky D, Zwahlen D, Oehler C, Champion A Cancers (Basel). 2024; 16(10).

PMID: 38791953 PMC: 11120349. DOI: 10.3390/cancers16101875.


Neuropancreatology: The Nervous System and Pain Management in Pancreatic Diseases.

Nicoletti A, Vitale F, Paratore M, Quero G, Negri M, Nista E Life (Basel). 2024; 14(3).

PMID: 38541624 PMC: 10970869. DOI: 10.3390/life14030299.


Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.


References
1.
Wong H, Yu L, Lam E, Tai E, Wu W, Cho C . Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol. 2007; 221(3):261-7. DOI: 10.1016/j.taap.2007.04.002. View

2.
Mancuso A, Calabro F, Sternberg C . Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol. 2006; 58(3):231-41. DOI: 10.1016/j.critrevonc.2006.02.004. View

3.
Schuller H, Tithof P, Williams M, Plummer 3rd H . The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999; 59(18):4510-5. View

4.
Wanamaker C, Christianson J, Green W . Regulation of nicotinic acetylcholine receptor assembly. Ann N Y Acad Sci. 2003; 998:66-80. DOI: 10.1196/annals.1254.009. View

5.
Hruban R, Fukushima N . Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 2007; 20 Suppl 1:S61-70. DOI: 10.1038/modpathol.3800685. View